SCHEMBL19857573

SCHEMBL19857573

Cc1cc2cccc(C(N)=O)c2o1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 1/20 0.50
ADORA2A P29274 1/20 0.48
ADORA2B P29275 1/20 0.48
ADORA1 P30542 1/20 0.48
CRBN Q96SW2 1/20 0.47
PARP1 P09874 6/20 0.46
MAOA P21397 3/20 0.46
ALDH1A1 P00352 4/20 0.46
KDM4E B2RXH2 2/20 0.46
GAA P10253 1/20 0.46
KMT2A Q03164 1/20 0.45
MRGPRX1 Q96LB2 1/20 0.43
MAOB P27338 2/20 0.41
HPGD P15428 2/20 0.41
MAPT P10636 1/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
PDPK1 O15530 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3306573 0.84 MAOA (0.50) CRBNMAOAALDH1A1KDM4EMRGPRX1
SCHEMBL2260801 0.81 CRBN (0.46) CRBNMAOAALDH1A1MRGPRX1MAOB
SCHEMBL30367973 0.81 ALDH1A1 (0.62) LCKADORA2AADORA2BADORA1PARP1
SCHEMBL28258201 0.80 CRBN (0.54) CRBNMAOAALDH1A1KDM4EGAA
SCHEMBL3965575 0.80 CRBN (0.48) CRBNMAOAALDH1A1KDM4EMRGPRX1
SCHEMBL25649885 0.79 PARP1 (0.51) LCKADORA2AADORA2BADORA1PARP1
SCHEMBL21039188 0.78 ALDH1A1 (0.51) LCKADORA2AADORA2BADORA1PARP1
SCHEMBL29891436 0.78 ALDH1A1 (0.51) LCKADORA2AADORA2BADORA1PARP1
SCHEMBL28633012 0.77 LCK (0.48) LCKADORA2AADORA2BADORA1PARP1
SCHEMBL28629962 0.77 LCK (0.48) LCKADORA2AADORA2BADORA1PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115515679-A Heterocyclic amides and their use for modulating splicing 雷密克斯医疗公司 2022-12-23 CN disclosed
US-10174005-B2 Fused pyrimidines as inhibitors of p97 complex CLEAVE BIOSCIENCES, INC. (US) 2019-01-08 US disclosed
US-20180044325-A1 FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX CLEAVE BIOSCIENCES, INC. 2018-02-15 US disclosed
CN-107406434-A As 5 HT4The amide compound of receptor stimulating agent 苏文生命科学有限公司 2017-11-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10174005-B2 Fused pyrimidines as inhibitors of p97 complex WDR77, POP1, PSMG3 LCK 3174/4885ADORA2A 4380/4885ADORA2B 4408/4885
US-20180044325-A1 FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX WDR77, POP1, PSMG3 LCK 3181/4885ADORA2A 4381/4885ADORA2B 4399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.